Orthocell (ASX:OCC) has received a Chinese patent covering the manufacture of its Celgro collagen-based scaffold for the surgical repair of damaged soft tissue such as tendons, cartilage and eardrums.
The company was previously granted patents for this method in Singapore and New Zealand.
In addition, the Celgro technology platform has been validated by its recent partnership with world-leading bone substitute firm BONESUPPORT to use Celgro to create new bone repair products.
Orthocell’s novel methodology for producing a bio-scaffold device overcomes or alleviates some of the major problems associated with other currently available bio-scaffolds which can include:
- Poor surface chemistry which provides suboptimal attachment of cells;
- Acidic by-products which degrade the local pH such that cell micro-environments are disrupted;
- Immune reactions due to presence of residual foreign cells from the host; and
- Lack of suitable pore size and structure and lack of sufficient mechanical properties required to withstand the harsh environments in which bio-scaffolds are regularly used.
The company’s Celgro technology is a next-generation collagen-based scaffold to support tissue growth and repair. Its unique characteristics include:
- Cell free matrix that is devoid of contaminants and reactive DNA;
- Tissue friendly structure that facilitates tissue in-growth and repair;
- Mechanical strength and pliability for tissue support during healing;
- Australian-sourced raw materials able to be reproduced in large commercial quantities thus eliminating disease transmission concerns.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.